Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial

J Antimicrob Chemother. 2018 Apr 1;73(4):1020-1024. doi: 10.1093/jac/dkx498.

Abstract

Background: The OPTIPRIM-ANRS 147 trial compared intensive combination ART (darunavir/ritonavir, tenofovir disoproxil fumarate/emtricitabine, raltegravir and maraviroc) started early during primary HIV-1 infection with standard tritherapy with darunavir/ritonavir, tenofovir disoproxil fumarate and emtricitabine. From month 6 to 18, the percentage of viral load values <50 copies/mL was lower in the pentatherapy arm than in the tritherapy arm. Here we compared antiretroviral drug concentrations between the two arms.

Methods: Plasma samples were collected from 50 patients at various times after drug administration. A Bayesian approach based on published population pharmacokinetic models was used to estimate residual drug concentrations (Ctrough) and exposures (AUC) in each patient. A mixed linear regression model was then used to compare the AUC and Ctrough values of each drug used in both groups.

Results: Published models adequately described our data and could be used to predict Ctrough and AUC. No significant difference in tenofovir disoproxil fumarate, emtricitabine and ritonavir parameters was found between the two arms. However, darunavir Ctrough and AUC were significantly lower in the pentatherapy arm than in the tritherapy arm (P = 0.03 and P = 0.04, respectively).

Conclusions: Adding maraviroc and raltegravir to darunavir-based tritherapy decreased darunavir concentrations. Compliance issues, maraviroc-darunavir interaction and raltegravir-darunavir interaction were suspected and may affect the kinetics of viral decay during pentatherapy. A specific pharmacokinetic interaction study is needed to explore the interactions between darunavir and maraviroc and raltegravir.

Publication types

  • Clinical Trial, Phase III
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / pharmacokinetics*
  • Darunavir / administration & dosage
  • Darunavir / pharmacokinetics*
  • Female
  • HIV Infections / drug therapy
  • HIV-1 / isolation & purification
  • Humans
  • Male
  • Maraviroc / administration & dosage
  • Maraviroc / pharmacokinetics*
  • Middle Aged
  • Models, Statistical
  • Plasma / chemistry*
  • Raltegravir Potassium / administration & dosage
  • Raltegravir Potassium / pharmacokinetics*
  • Ritonavir / administration & dosage
  • Ritonavir / pharmacokinetics
  • Viral Load
  • Young Adult

Substances

  • Anti-HIV Agents
  • Raltegravir Potassium
  • Maraviroc
  • Ritonavir
  • Darunavir